HIV vaccines comprising one or more population episensus antigens
Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.
1. A vector comprising a human cytomegalovirus (HCMV) backbone or a rhesus cytomegalovirus (RhCMV) backbone, wherein the HCMV or RhCMV backbone comprises a nucleic acid sequence encoding an antigen comprising the amino acid sequence of SEQ ID NO:721.
2. The vector of claim 1 , wherein:
i) the HCMV or RhCMV backbone lacks the UL130-128 gene region,
ii) the HCMV or RhCMV backbone lacks the UL82 gene encoding the tegument protein pp71, or
iii) the HCMV or RhCMV backbone lacks the UL130-128 gene region and the UL82 gene encoding the tegument protein pp71.
3. The vector of claim 1 , wherein the antigen further comprises the amino acid sequence of any one of SEQ ID NOs: 722-725.
4. The vector of claim 1 , wherein the antigen further comprises the amino acid sequence of SEQ ID NO: 725.
5. The vector of claim 4 , wherein the HCMV or RhCMV backbone lacks the UL130-128 gene region and the UL82 gene encoding the tegument protein pp71.
6. The vector of claim 4 , wherein the antigen comprises the amino acid sequence of SEQ ID NO: 708.
7. The vector of claim 6 , wherein the HCMV or RhCMV backbone lacks the UL130-128 gene region and the UL82 gene encoding the tegument protein pp71.
8. The vector of claim 1 , wherein the antigen further comprises the amino acid sequence of any one of SEQ ID NOs: 709-712 and 726-729.
9. The vector of claim 1 , wherein the antigen further comprises the amino acid sequence of SEQ ID NO: 712.
10. The vector of claim 9 , wherein the HCMV or RhCMV backbone lacks the UL130-128 gene region and the UL82 gene encoding the tegument protein pp71.
11. The vector of claim 4 , wherein the antigen further comprises the amino acid sequence of SEQ ID NO: 712.
12. The vector of claim 11 , wherein the HCMV or RhCMV backbone lacks the UL130-128 gene region and the UL82 gene encoding the tegument protein pp71.
13. A method of inducing an anti-HIV-1 immune response in a subject in need thereof, comprising administering to the subject an effective amount of the vector of claim 1 .
14. A method of inducing an anti-HIV-1 immune response in a subject in need thereof, comprising administering to the subject an effective amount of the vector of claim 2 .
15. A method of inducing an anti-HIV-1 immune response in a subject in need thereof, comprising administering to the subject an effective amount of the vector of claim 4 .
16. A method of inducing an anti-HIV-1 immune response in a subject in need thereof, comprising administering to the subject an effective amount of the vector of claim 5 .
17. A method of inducing an anti-HIV-1 immune response in a subject in need thereof, comprising administering to the subject an effective amount of the vector of claim 6 .
18. A method of inducing an anti-HIV-1 immune response in a subject in need thereof, comprising administering to the subject an effective amount of the vector of claim 7 .
19. A method of inducing an anti-HIV-1 immune response in a subject in need thereof, comprising administering to the subject an effective amount of the vector of claim 9 .
20. A method of inducing an anti-HIV-1 immune response in a subject in need thereof, comprising administering to the subject an effective amount of the vector of claim 10 .
21. A method of inducing an anti-HIV-1 immune response in a subject in need thereof, comprising administering to the subject an effective amount of the vector of claim 11 .
22. A method of inducing an anti-HIV-1 immune response in a subject in need thereof, comprising administering to the subject an effective amount of the vector of claim 12 .
23. A method of inducing an anti-HIV-1 effector memory T cell response in a subject in need thereof, comprising administering to the subject an effective amount of the vector of claim 1 .
24. A method of inducing an anti-HIV-1 effector memory T cell response in a subject in need thereof, comprising administering to the subject an effective amount of the vector of claim 2 .